Detalhe da pesquisa
1.
Implementation of in vitro glycoengineering of monoclonal antibodies into downstream processing of industrial production.
Glycobiology
; 32(2): 123-135, 2022 03 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34939096
2.
Two N-terminally truncated variants of human ß-galactoside α2,6 sialyltransferase I with distinct properties for in vitro protein glycosylation.
Glycobiology
; 26(10): 1097-1106, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27102286
3.
Clearance of therapeutic antibody glycoforms after subcutaneous and intravenous injection in a porcine model.
MAbs
; 14(1): 2145929, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36383465
4.
Glycoform-resolved pharmacokinetic studies in a rat model employing glycoengineered variants of a therapeutic monoclonal antibody.
MAbs
; 13(1): 1865596, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-33382957
5.
Interaction analysis of glycoengineered antibodies with CD16a: a native mass spectrometry approach.
MAbs
; 12(1): 1736975, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32167012
6.
The Impact of Immunoglobulin G1 Fc Sialylation on Backbone Amide H/D Exchange.
Antibodies (Basel)
; 8(4)2019 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31581521
7.
Effects of sialic acid linkage on antibody-fragment crystallizable receptor binding and antibody dependent cytotoxicity depend on levels of fucosylation/bisecting.
Bioanalysis
; 11(15): 1437-1449, 2019 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-31490109
8.
In vitro glycoengineering of IgG1 and its effect on Fc receptor binding and ADCC activity.
PLoS One
; 10(8): e0134949, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26266936